This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Steris (STE) Q1 Earnings on the Horizon: Analysts' Insights on Key Performance Measures
by Zacks Equity Research
Looking beyond Wall Street's top-and-bottom-line estimate forecasts for Steris (STE), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended June 2025.
Will Healthcare Growth Help STE Beat on Q1 Earnings?
by Zacks Equity Research
STERIS is likely to have experienced a strong Q1 with 14.3% EPS growth as Healthcare and AST segments show solid momentum.
Alphatec (ATEC) Beats Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Alphatec (ATEC) delivered earnings and revenue surprises of +133.33% and +3.65%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Globus Medical (GMED) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Globus Medical (GMED) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Steris (STE) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Steris (STE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Steris (STE) Loses 6% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
by Zacks Equity Research
Steris (STE) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Should You Continue to Hold STERIS Stock in Your Portfolio Now?
by Zacks Equity Research
STE rides on strong Healthcare and AST growth, but macro pressures and customer consolidation cloud its outlook.
Why Is Steris (STE) Down 1.8% Since Last Earnings Report?
by Zacks Equity Research
Steris (STE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
SOLV's Strong Q1 Signals Turnaround: Is the Stock Worth Betting Now?
by Zacks Equity Research
Solventum beats Q1 estimates, raises guidance, and powers ahead with transformation despite looming tariff headwinds.
Alcon Stock Rises Following the FDA Approval of TRYPTYR
by Zacks Equity Research
FDA approves ALC's TRYPTYR, a new dry eye treatment with rapid tear production. The approval is supported by strong Phase 3 trial results.
Abbott Stock Gains Following FDA Approval of the Tendyne System
by Zacks Equity Research
ABT wins FDA approval for its Tendyne TMVR system, offering a minimally invasive mitral valve replacement for high-risk patients with severe MAC.
Prestige Consumer Gains 35.7% in a Year: What's Driving the Stock?
by Zacks Equity Research
PBH stock jumps on the back of brand strength, e-commerce gains and smart acquisitions despite tariff and foreign exchange headwinds.
Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
QGEN Stock Might Gain Following New Partnership With ID Solutions
by Zacks Equity Research
QGEN teams up with ID Solutions to boost QIAcuity's reach in oncology dPCR assays, aiming to strengthen its cancer research leadership.
Walgreens Opens New Micro-Fulfillment Center in Brooklyn Park
by Zacks Equity Research
WBA expands micro-fulfillment with a new facility in Brooklyn Park, MN. This will support nearly 200 Walgreens stores across the Midwest.
Are Options Traders Betting on a Big Move in STERIS (STE) Stock?
by Zacks Equity Research
Investors need to pay close attention to STERIS (STE) stock based on the movements in the options market lately.
AST Business Growth & Strategic Acquisitions Support STERIS Stock
by Zacks Equity Research
STE frequently engages in strategic acquisitions and joint ventures to optimize its portfolio of businesses.
Is it the Right Time to Hold STERIS Stock in Your Portfolio?
by Zacks Equity Research
STE stays on investors' radars due to the strength of its Healthcare arm and strong rebound potential in the AST segment.
Neogen Stock Gains Following Strategic Alliance With Syngenta
by Zacks Equity Research
NEOG inks a new strategic licensing and supply agreement with Syngenta to market and sell the latter's Talon-G and Talon Weatherblok XT rodenticides in the United States and Canada.
Deciphering Steris (STE) International Revenue Trends
by Zacks Equity Research
Examine Steris' (STE) international revenue patterns and their implications on Wall Street's forecasts and the prospective trajectory of the stock.
Veracyte Stock Surges 30.9% in a Year: What's Driving the Rally?
by Zacks Equity Research
Strength in VCYT's Afirma and Decipher tests continues to draw investors' attention.
ALGN Stock Might Rise Following the NMPA Approval in China
by Zacks Equity Research
Align Technology receives approval from the National Medical Products Administration in China for its Invisalign Palatal Expander System.
Should Edwards Lifesciences Stock Remain in Your Portfolio Now?
by Zacks Equity Research
EW stock is on investors' radars due to the promising structural heart opportunities and impressive TMTT portfolio.
STE Q4 Earnings Beat, Margins Expand, Stock Up in Aftermarket
by Zacks Equity Research
STERIS' fourth-quarter fiscal 2025 results reflect strong growth momentum in Healthcare and AST revenues.